{"id":34819,"date":"2026-03-23T17:51:00","date_gmt":"2026-03-23T12:21:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34819"},"modified":"2026-03-23T17:02:04","modified_gmt":"2026-03-23T11:32:04","slug":"icotyde-for-plaque-psoriasis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis","title":{"rendered":"J&amp;J and Protagonist\u2019s ICOTYDE Ushers in First-in-Class Oral IL-23 Therapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fe0a644e58e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fe0a644e58e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\/#A_New_Chapter_in_Plaque_Psoriasis\" >A New Chapter in Plaque Psoriasis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\/#ICOTYDE_Targeted_Science_in_a_Daily_Pill\" >ICOTYDE: Targeted Science in a Daily Pill<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\/#J_J%E2%80%93Protagonist_A_Long%E2%80%91Horizon_Collaboration_Pays_Off\" >J&amp;J\u2013Protagonist: A Long\u2011Horizon Collaboration Pays Off<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\/#Beyond_Skin_Building_an_IL%E2%80%9123%E2%80%91Centric_Franchise\" >Beyond Skin: Building an IL\u201123\u2011Centric Franchise<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\/#Redesigning_the_Treatment_Conversation\" >Redesigning the Treatment Conversation<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Johnson &amp; Johnson and Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents (12+ years, \u226540 kg).<\/em><\/li>\n\n\n\n<li><em>Once-daily 200 mg oral tablet blocks IL-23 signaling with high affinity; taken on an empty stomach before food for biologic-like efficacy without injections.<\/em><\/li>\n\n\n\n<li><em>Four pivotal trials (2,500 patients) showed ~70% achieving clear\/almost clear skin (IGA 0\/1) and 55% PASI 90 at Week 16; superior to SOTYKTU; safety similar to placebo (1.1% difference at Week 16, no new signals at Week 52).<\/em><\/li>\n<\/ul>\n\n\n\n<p><strong>Johnson &amp; Johnson and Protagonist Therapeutics\u2019 ICOTYDE (icotrokinra)<\/strong> approval marks a pivotal inflection point in <a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\">plaque psoriasis treatment<\/a>, marrying the power of IL\u201123 pathway blockade with the simplicity of a once\u2011daily oral pill. Positioned as the first and only targeted oral IL\u201123 receptor peptide therapy, ICOTYDE is set to redefine first\u2011line systemic care for patients long trapped in a cycle of inadequate topicals and compromise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-new-chapter-in-plaque-psoriasis\"><span class=\"ez-toc-section\" id=\"A_New_Chapter_in_Plaque_Psoriasis\"><\/span><strong>A New Chapter in Plaque Psoriasis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Plaque psoriasis remains one of the most visible and burdensome immune\u2011mediated diseases, affecting more than <strong>8 million<\/strong> Americans and over <strong>125 million<\/strong> people worldwide, with nearly one\u2011quarter of cases classified as moderate to severe. Beyond the hallmark inflamed, scaly plaques on the scalp, elbows, knees, torso, and high\u2011impact sites such as the genitals, hands, and feet, psoriasis erodes emotional health, relationships, and daily functioning.<\/p>\n\n\n\n<p>For years, treatment conversations have been polarized: potent injectable biologics at one end and often\u2011inadequate topical therapies at the other, with a stubborn gap in between. International Psoriasis Council guidance now clearly recommends transitioning to systemic therapy when two cycles of four\u2011week topical regimens fail, underscoring how many patients require more than creams and ointments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-icotyde-targeted-science-in-a-daily-pill\"><span class=\"ez-toc-section\" id=\"ICOTYDE_Targeted_Science_in_a_Daily_Pill\"><\/span><strong>ICOTYDE: Targeted Science in a Daily Pill<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>ICOTYDE is an <a href=\"https:\/\/www.delveinsight.com\/report-store\/interleukin-23-inhibitors-market\">interleukin\u201123 receptor antagonist<\/a> and the first and only targeted oral peptide designed to precisely block IL\u201123R, a key upstream driver of the inflammatory cascade in moderate\u2011to\u2011severe plaque psoriasis. By binding the IL\u201123 receptor with high affinity and potently inhibiting IL\u201123 signaling in human T cells, ICOTYDE aims to deliver biologic\u2011like disease control without needles.<\/p>\n\n\n\n<p>The U.S. FDA has approved ICOTYDE for adults and pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy, directly addressing a broad segment of patients underserved by current care algorithms. Dosed as a single 200\u2011mg tablet once daily upon waking, on an empty stomach and at least 30 minutes before food, the regimen is intentionally built to integrate seamlessly into everyday routines.<\/p>\n\n\n\n<p>ICOTYDE\u2019s label rests on an unusually comprehensive <strong>Phase 3 program, ICONIC<\/strong>, spanning four pivotal studies and approximately 2,500 patients across adults and adolescents. The program simultaneously interrogated efficacy and safety in classic plaque disease, high\u2011impact sites such as scalp and genital psoriasis, and in duplicate head\u2011to\u2011head trials versus an active comparator.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"616\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-1024x616.webp\" alt=\"ICOTYDE-Development-Timeline\" class=\"wp-image-34822\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-1024x616.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-300x181.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-150x90.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-768x462.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline-1536x924.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/ICOTYDE-Development-Timeline.webp 1755w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Across these Phase 3 studies, ICOTYDE met all primary endpoints and delivered robust skin clearance outcomes that push the boundaries of what clinicians expect from an oral agent. In head\u2011to\u2011head superiority trials, about 70% of patients achieved clear or almost clear skin (IGA 0\/1), while 55% reached PASI 90 at Week 16, efficacy levels more typically associated with injectable biologics than with pills.<\/p>\n\n\n\n<p>Equally critical is the safety story: rates of adverse reactions with ICOTYDE were within 1.1% of placebo through Week 16, and no new safety signals emerged through Week 52, supporting long\u2011term use in a chronic disease that demands durable control. This balance of deep efficacy and a favorable safety profile is a central pillar of how ICOTYDE is being positioned as a potential new standard in systemic psoriasis care.<\/p>\n\n\n\n<p>Regulators have explicitly framed ICOTYDE as a first\u2011line systemic option for <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-to-severe-plaque-psoriasis-market\">moderate\u2011to\u2011severe plaque psoriasis<\/a>, opening the door for earlier, targeted intervention. The drug is also the first FDA\u2011approved daily peptide pill that targets the IL\u201123 receptor and delivers complete skin clearance in plaque psoriasis, creating a new mechanistic and formulation class within the oral space.<\/p>\n\n\n\n<p>That differentiation matters in a competitive landscape where <strong>Bristol Myers Squibb\u2019s oral TYK2 inhibitor SOTYKTU<\/strong> previously enjoyed a multi\u2011year head start and has become a key growth driver. Data from <strong>ICONIC\u2011ADVANCE 1 and 2<\/strong> showed ICOTYDE not only outperformed placebo but also demonstrated significant superiority to SOTYKTU in achieving high\u2011level clearance measures, positioning J&amp;J\u2019s pill as a formidable new entrant in the oral systemic segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-j-amp-j-protagonist-a-long-horizon-collaboration-pays-off\"><span class=\"ez-toc-section\" id=\"J_J%E2%80%93Protagonist_A_Long%E2%80%91Horizon_Collaboration_Pays_Off\"><\/span><strong>J&amp;J\u2013Protagonist: A Long\u2011Horizon Collaboration Pays Off<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>ICOTYDE is the product of a long\u2011running strategic partnership between Johnson &amp; Johnson and Protagonist Therapeutics that began in 2017, built around <strong>Protagonist\u2019s proprietary peptide technology platform<\/strong>. Discovered jointly by scientists from both companies, ICOTYDE advanced through Phase 1 under Protagonist\u2019s leadership, after which J&amp;J assumed responsibility for late\u2011stage development and global commercialization.<\/p>\n\n\n\n<p>\u200bThe FDA green light triggers a <strong>$50 million<\/strong> milestone payment to Protagonist, with the potential for up to <strong>$580 million<\/strong> in additional regulatory and sales milestones and tiered royalties ranging from <strong>6% to 10%<\/strong> on global net sales. For Protagonist, these economics and validation of its platform, alongside the pending FDA decision for rusfertide, signal the beginning of a multi\u2011year, product\u2011driven growth cycle.<\/p>\n\n\n\n<p>\u200bFor J&amp;J, ICOTYDE is strategically timed as the company navigates loss of exclusivity for its immunology blockbuster STELARA and works to extend its leadership via newer assets like TREMFYA and now this first\u2011in\u2011class <a href=\"https:\/\/www.delveinsight.com\/report-store\/interleukin-23-il-23-inhibitor-pipeline-insight\">oral IL\u201123R peptide<\/a>. The approval reinforces J&amp;J\u2019s broader immunology vision: translating cutting\u2011edge science into accessible, patient\u2011centric therapies that can be deployed earlier in the disease journey.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beyond-skin-building-an-il-23-centric-franchise\"><span class=\"ez-toc-section\" id=\"Beyond_Skin_Building_an_IL%E2%80%9123%E2%80%91Centric_Franchise\"><\/span><strong>Beyond Skin: Building an IL\u201123\u2011Centric Franchise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While ICOTYDE\u2019s first indication is moderate\u2011to\u2011severe plaque psoriasis, its development arc clearly signals ambitions that go far beyond the skin. Multiple Phase 3 ICONIC studies are underway in IL\u201123\u2011driven conditions, including active psoriatic arthritis (<strong>ICONIC\u2011PsA 1 and 2<\/strong>), moderately\u2011to\u2011severely active ulcerative colitis (<strong>ICONIC\u2011UC<\/strong>), and moderately\u2011to\u2011severely active Crohn\u2019s disease (<strong>ICONIC\u2011CD<\/strong>).<\/p>\n\n\n\n<p>If successful, these programs could enable J&amp;J and Protagonist to build a multi\u2011indication, oral IL\u201123R franchise that complements existing injectable IL\u201123 biologics while speaking directly to patients\u2019 demand for less invasive, more convenient options. Such an evolution would not only expand the commercial footprint of ICOTYDE but also reinforce IL\u201123 as a central axis in systemic inflammatory disease management.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-redesigning-the-treatment-conversation\"><span class=\"ez-toc-section\" id=\"Redesigning_the_Treatment_Conversation\"><\/span><strong>Redesigning the Treatment Conversation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Perhaps the most profound impact of ICOTYDE will be on the everyday treatment decisions made in dermatology clinics. With a once\u2011daily targeted oral peptide now available as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\">first\u2011line systemic option for plaque psoriasis<\/a>, the conversation can move from \u201cHow long can we stretch topicals?\u201d to \u201cHow quickly can we achieve and sustain deep skin clearance with a regimen that fits the patient\u2019s life?\u201d<\/p>\n\n\n\n<p>For patients who have long associated high\u2011efficacy psoriasis control with needles, infusion centers, or complex dosing schedules, ICOTYDE introduces a new proposition: biologic\u2011like outcomes with the familiarity of a pill and a safety profile that closely mirrors placebo over the first 16 weeks. For J&amp;J and Protagonist, it is both a scientific milestone and a strategic beachhead, one that could reshape the systemic psoriasis landscape, and possibly the broader IL\u201123\u2011driven disease space, for years to come.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-1024x194.webp\" alt=\"Plaque Psoriasis Market Outlook\" class=\"wp-image-34821\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/Plaque-Psoriasis-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Johnson &amp; Johnson and Protagonist Therapeutics\u2019 ICOTYDE (icotrokinra) approval marks a pivotal inflection point in plaque psoriasis treatment, marrying the power of IL\u201123 pathway blockade with the simplicity of a once\u2011daily oral pill. Positioned as the first and only targeted oral IL\u201123 receptor peptide therapy, ICOTYDE is set to redefine first\u2011line systemic care for [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34823,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22930,22931,21382,1546,20564,20562],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-34819","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-icotyde","tag-il-23","tag-moderate-to-severe-plaque-psoriasis","tag-plaque-psoriasis","tag-plaque-psoriasis-clinical-trials","tag-plaque-psoriasis-drugs","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ICOTYDE Emerges as a First-Line Contender in Plaque Psoriasis<\/title>\n<meta name=\"description\" content=\"J &amp; J and Protagonist received FDA approval for ICOTYDE, the first targeted oral IL-23 receptor for moderate-to-severe plaque psoriasis\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICOTYDE Emerges as a First-Line Contender in Plaque Psoriasis\" \/>\n<meta property=\"og:description\" content=\"J &amp; J and Protagonist received FDA approval for ICOTYDE, the first targeted oral IL-23 receptor for moderate-to-severe plaque psoriasis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T12:21:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ICOTYDE Emerges as a First-Line Contender in Plaque Psoriasis","description":"J & J and Protagonist received FDA approval for ICOTYDE, the first targeted oral IL-23 receptor for moderate-to-severe plaque psoriasis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis","og_locale":"en_US","og_type":"article","og_title":"ICOTYDE Emerges as a First-Line Contender in Plaque Psoriasis","og_description":"J & J and Protagonist received FDA approval for ICOTYDE, the first targeted oral IL-23 receptor for moderate-to-severe plaque psoriasis","og_url":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-23T12:21:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis","url":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis","name":"ICOTYDE Emerges as a First-Line Contender in Plaque Psoriasis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis.webp","datePublished":"2026-03-23T12:21:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"J & J and Protagonist received FDA approval for ICOTYDE, the first targeted oral IL-23 receptor for moderate-to-severe plaque psoriasis","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/icotyde-for-plaque-psoriasis#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis.webp","width":466,"height":284,"caption":"icotyde-for-plaque-psoriasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/icotyde-for-plaque-psoriasis-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ICOTYDE<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IL-23<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Moderate to Severe Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Plaque psoriasis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Plaque psoriasis drugs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ICOTYDE<\/span>","<span class=\"advgb-post-tax-term\">IL-23<\/span>","<span class=\"advgb-post-tax-term\">Moderate to Severe Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Plaque psoriasis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Plaque psoriasis drugs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 23, 2026","modified":"Updated on Mar 23, 2026"},"absolute_dates_time":{"created":"Posted on Mar 23, 2026 5:51 pm","modified":"Updated on Mar 23, 2026 5:02 pm"},"featured_img_caption":"icotyde-for-plaque-psoriasis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34819"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34819\/revisions"}],"predecessor-version":[{"id":34825,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34819\/revisions\/34825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34823"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34819"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34819"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}